KYMR - kymeratx.com Trailing Twelve Months Revenue Growth

Kymera Therapeutics (KYMR) is developing targeted therapies through alliances with pharmaceutical giants, aiming to complete late-stage trials for its oncology drugs. The company's TTM annual revenue growth rate reflects its development dynamics, with this metric reaching 133.50. Business growth relies on protein degradation technology, the success of which depends on FDA approvals and the results for the drug KT-474.
Kymera - analytical breakdowns and key metrics (KYMR)

Investors use this metric to distinguish real business scaling from short-term market volatility. It measures the percentage deviation of current trailing twelve-month (TTM) total revenue from the same window of the previous year. By analyzing the TTM year-over-year revenue growth rate on GURU.Markets, one can assess the stability of cash flows. For Kymera Therapeutics (KYMR), the absence of sales confirms the platform's development stage and a high dependence on external investment.